Carlos Doti

In my role at AstraZeneca, I am responsible for developing the medical strategy for the haematology franchise supporting the launches of Calquence (acalabrutinib) worldwide and building up capabilities for AstraZeneca’s entry into acute myeloid leukaemia, myelodysplastic syndromes and aggressive non-Hodgkin lymphomas.

I am a haematologist by training and have extensive medical knowledge of cancer and haematologic malignancies. I am passionate about patients and aim to deliver treatments that have a real impact for people living with cancer across every aspect of their disease.

I joined AstraZeneca in 2016, first as a Medical Director and then as the Oncology Business Unit Director in Argentina and Uruguay. Following this, I served as the lead of AstraZeneca’s haematology commercial team where I oversaw a cross-functional team supporting acalabrutinib in multiple geographies including Latin America, the Middle East and Asia-Pacific.

I have more than a decade of experience within the pharmaceutical industry, and previously served in medical affairs roles at Novo Nordisk A/S and Pfizer. During this time, I have gained extensive experience developing and executing portfolio / brand strategy, product launches and pricing and market access in the emerging markets.

My work is supported by more than 70 congress presentations and several peer-reviewed publications. I have also served as an investigator in more than 25 clinical trials in haemostasis, onco-haematology and infectious disease.

Prior to joining the private sector, I was trained in haematology at both Mount Sinai Medical Center in New York, and the British Hospital in Buenos Aires, where I served as an attending physician.